Hasan Cem Irkilata

Hasan Cem Irkilata

Auto-generated profile, based on publicly available information

Hasan Cem Irkilata

Department of Urology Private Lokman Hekim Istanbul Hospital Istanbul Turkey

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2006 in Archives of Medical Research
Verified
Journal Article
Closed access
OEOsman Erogul
Osman Erogul
EOEmin Oztas
Emin Oztas
IYIbrahim Yildirim
Ibrahim Yildirim
TKTayfun Kir
Tayfun Kir
EAEmin Aydur
Emin Aydur
APAhmet Fuat Peker
Ahmet Fuat Peker

1 October 2007 in Urology
Verified
Journal Article
Closed access
MDMurat Dayanc
Murat Dayanc
YKYusuf Kibar
Yusuf Kibar
HIHasan Cem Irkilata
Hasan Cem Irkilata
EDErkan Demir
Erkan Demir
LTLutfu Tahmaz
Lutfu Tahmaz
APAhmet Fuat Peker
Ahmet Fuat Peker

1 August 2014 in Journal of Urology
Verified
Journal Article
Closed access
MGMehmet İlKer Gökçe
Mehmet İlKer Gökçe
PHParviz Hajıyev
Parviz Hajıyev
ESEvren Süer
Evren Süer
YKYusuf Kibar
Yusuf Kibar
MSMesrur Selçuk Sılay
Mesrur Selçuk Sılay
BBBerk Burgu
Berk Burgu
Relapse after cessation of desmopressin is an important problem in treating patients with enuresis. Structured withdrawal of desmopressin tablets has been shown to decrease relapse rates. However, scientific data are lacking on the structured withdrawal of the fast melting oral formulation of desmopressin. We compared relapse rates of structured withdrawal using placebo and direct cessation in a population of patients with enuresis who were desmopressin responders. Patients diagnosed with enuresis and responding to desmopressin from 13 different centers were involved in the study. Patients were randomized into 4 groups. Two different structured withdrawal strategies were compared to placebo and direct withdrawal. Sample size was estimated as 240 (60 patients in each group), with a power of 0.80 and an effect size of 30%. Randomization was performed using NCSS statistical software (NCSS, Kaysville, Utah) from a single center. The relapse rates of the groups were compared using chi-square testing. Logistic regression analysis was performed to define the independent factors having an effect on relapse rates. Desmopressin treatment was initiated in 421 patients, and 259 patients were eligible for randomization. Relapse rates were 39 (1%) and 42 (4%) for the structured withdrawal groups, which were significantly less than for direct withdrawal (55, 3%) and placebo (53, 1%). Logistic regression analysis revealed that initial effective dose of 240 μcg, greater number of wet nights before treatment and nonstructured withdrawal were associated with higher relapse rates. We found that structured withdrawal with the fast melting oral formulation of desmopressin results in decreased relapse rates. Application of a structured withdrawal program was also an independent factor associated with reduced relapse rates, together with lower initial effective dose and number of wet nights per week. Relapse after cessation of desmopressin is an important problem, and in this study structured withdrawal was observed to be associated with decreased relapse rates compared to placebo and direct withdrawal.

1 June 2010 in Urology
Verified
Journal Article
Closed access
YKYusuf Kibar
Yusuf Kibar
MPMesut Piskin
Mesut Piskin
HIHasan C. Irkılata
Hasan C. Irkılata
EAEmin Aydur
Emin Aydur
FGFaysal Gok
Faysal Gok
MDMurat Dayanc
Murat Dayanc

31 July 2009 in Urology
Verified
Journal Article
Closed access
OYOguzhan Yildiz
Oguzhan Yildiz
MSMelik Seyrek
Melik Seyrek
HIHasan Cem Irkilata
Hasan Cem Irkilata
IYIbrahim Yildirim
Ibrahim Yildirim
LTLutfu Tahmaz
Lutfu Tahmaz
MDMurat Dayanc
Murat Dayanc

1 March 2005 in Urology
Verified
Journal Article
Closed access
YÖYaşar Özgök
Yaşar Özgök
MKMete Kilciler
Mete Kilciler
EAEmin Aydur
Emin Aydur
MSMutlu Saglam
Mutlu Saglam
HIHasan Cem Irkılata
Hasan Cem Irkılata
DEDogan Erduran
Dogan Erduran